Related references
Note: Only part of the references are listed.Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Aniruddha J. Deshpande et al.
BLOOD (2013)
MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism
Edward Allan R. Sison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
Edward Allan R. Sison et al.
MOLECULAR CANCER RESEARCH (2013)
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l
L. Chen et al.
LEUKEMIA (2013)
Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements
M. Nishi et al.
LEUKEMIA (2013)
Genetic Variants Modify Susceptibility to Leukemia in Infants: A Children's Oncology Group Report
Julie A. Ross et al.
PEDIATRIC BLOOD & CANCER (2013)
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study
Huining Kang et al.
BLOOD (2012)
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
Teena Bhatla et al.
BLOOD (2012)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia
D. J. P. M. Stumpel et al.
LEUKEMIA (2012)
Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report
U. Creutzig et al.
LEUKEMIA (2012)
Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+and MLL-germline acute lymphoblastic leukemia
M. C. Chillon et al.
LEUKEMIA (2012)
Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407
Wanda L. Salzer et al.
PEDIATRIC BLOOD & CANCER (2012)
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis
Anh Tram Nguyen et al.
BLOOD (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale
D. J. P. M. Stumpel et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants
Ronald W. Stam et al.
BLOOD (2010)
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting
Eric Schafer et al.
BLOOD (2010)
Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12
Christine J. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options
Dominique J. P. M. Stumpel et al.
BLOOD (2009)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Outcome of Recurrent or Refractory Acute Lymphoblastic Leukemia in Infants With MLL Gene Rearrangements: A Report From the Japan Infant Leukemia Study Group
Daisuke Tomizawa et al.
PEDIATRIC BLOOD & CANCER (2009)
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
D. Tomizawa et al.
LEUKEMIA (2007)
Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia
Ronald W. Stam et al.
BLOOD (2007)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Charles G. Mullighan et al.
NATURE (2007)
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner
P. Brown et al.
LEUKEMIA (2006)
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group
Joanne M. Hilden et al.
BLOOD (2006)
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
BES Gibson et al.
LEUKEMIA (2005)
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
RW Stam et al.
BLOOD (2005)
Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage
J Palle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Maternal diet and infant leukemia: The DNA topoisomerase II inhibitor hypothesis: A report from the Children's Oncology Group
LG Spector et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression
P Brown et al.
BLOOD (2005)
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype
NL Ramakers-van Woerden et al.
LEUKEMIA (2004)
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy
T Taketani et al.
BLOOD (2004)
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
SA Armstrong et al.
CANCER CELL (2003)
Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children
MT Smith et al.
BLOOD (2002)
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
CM Zwaan et al.
BLOOD (2002)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
SA Armstrong et al.
NATURE GENETICS (2002)
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia
JL Wiemels et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
R Strick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
